Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Phio Pharmaceuticals Corp. (PHIO)

Phio Pharmaceuticals completes first commercial-scale cGMP batch of PH-762

Neutral Impact 3 of 5 product/contract Written later

Phio Pharmaceuticals announced on October 13, 2026 that it successfully released its first commercial-scale cGMP batch of PH-762 drug substance. The batch will move on to final drug product steps for the planned Phase 2b clinical study, which the company expects to start in the first quarter of 2027. The filing reports an operational milestone and includes no financial results.

Key points

  • Batch was manufactured to established specifications and confirmed by a Certificate of Analysis and Certificate of Compliance
  • Planned Phase 2b clinical study of PH-762 is expected to begin in the first quarter of 2027
  • CEO Robert Bitterman said the work began about 16 months ago and is intended to mitigate key development and manufacturing risks

The filing

CompanyPhio Pharmaceuticals Corp. (PHIO)
Form8-K, current report
Filed with the SECOct 13, 2026, 8:41 AM ET
Accession number0001437749-26-032505

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.